Testing a novel drug to inhibit a lethal subtype of prostate cancer
This project aims to test a novel drug for a particularly aggressive and therapy resistant form of prostate cancer known as Neuroendocrine (NEPC) prostate cancer. Current clinical therapies are not effective at inhibiting the growth and spread of this subtype of prostate cancer and men diagnosed with neuroendocrine prostate cancer have a very poor prognosis.
NEPC is associated with poor clinical outcome and advanced disease. While the incidence of primary/localised prostate cancer with neuroendocrine features is only 1%, this increases to 25-30% in lethal stage disease. Despite the development of more aggressive therapies, the prognosis for patients with NEPC remains dismal with a median overall survival of approximately 7 months. The outcomes from this project are likely to identify a new therapy that can inhibit the growth of NEPC and provide the first effective targeted therapy for this disease subtype.
Investigators
| Dr Brett Hollier | APCRC-Q, IHBI, QUT, PAH |
| Prof Colleen Nelson | APCRC-Q, IHBI, QUT, PAH |
| Dr Benjamin Shepherd | PAH |
| Dr Nataly Stylianou | APCRC-Q, IHBI, QUT, PAH |
Duration
Funding
| PA Research Foundation | $100,000 |
